Background Biomarkers have revolutionized the management of colorectal cancer (CRC),
facilitating early detection, prevention, personalized treatment, and minimal residual disease …

In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a
minimally invasive approach for the diagnosis and management of patients with cancer and …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

PURPOSE Neoadjuvant chemotherapy (NAC) has potential advantages over standard
postoperative chemotherapy for locally advanced colon cancer but requires formal …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

Importance Detection of molecular residual disease and risk stratification as early as
possible may improve the treatment of patients with cancer. Efficient pragmatic tests are …

Summary Background The DoMore-v1-CRC marker was recently developed using deep
learning and conventional haematoxylin and eosin-stained tissue sections, and was …

Background Lymph node (LN) harvesting is associated with outcomes in colonic cancer. We
sought to interrogate whether a distinctive immune milieu of the primary tumour is …

Introduction Circulating tumor DNA (ctDNA) has been increasingly recognized as a
promising minimally-invasive biomarker that could identify patients with minimal residual …

Simple Summary The ability to predict or detect colorectal cancer (CRC) recurrence early
after surgery enables physicians to apply appropriate treatment plans and different follow-up …